Maze Therapeutics CMO Sells Remaining Direct Shareholding in $255,000 Transaction

Harold Bernstein, who serves as President of Research and Development and Chief Medical Officer at Maze Therapeutics (NASDAQ:MAZE), reported the sale of 9,705 shares of the company’s common stock, per an SEC Form 4 filing dated September 4, 2026. Based on the weighted average sale price disclosed in the filing — $26.22 per share — the transaction totaled roughly $255,000.

Form 4 filings are required under securities rules to disclose trades by company insiders, typically within two business days of the transaction. Such sales by executives are common and can reflect a variety of personal financial considerations, including diversification, tax planning, or scheduled trading plans, and do not by themselves signal anything about a company’s operating outlook.

The disclosure noted that the sale covered Bernstein’s entire direct stake in the company. Indirect holdings, if any, such as those held through trusts or other vehicles, would be reported separately.

About the Company

Maze Therapeutics is a clinical-stage biopharmaceutical company focused on precision medicine, developing targeted therapies for genetically defined kidney and metabolic diseases. The company carries a market capitalization of approximately $1.50 billion and directs substantial resources toward clinical development programs aimed at rare disease areas where treatment options remain limited.

As a clinical-stage firm, Maze does not yet generate product revenue, making its valuation tied largely to the progress of its pipeline through clinical trials and regulatory milestones. Insider trading activity at companies at this stage often draws attention from investors tracking management’s positioning, though analysts generally caution against reading too much into any single transaction.

What to watch

• Maze’s upcoming quarterly filings and earnings disclosures, which typically detail cash position and clinical development spending for the clinical-stage company.
• Updates on the company’s pipeline of therapies for genetically defined kidney and metabolic diseases, including trial progress and regulatory interactions.
• Additional Form 4 filings from Maze insiders, which may clarify whether the executive retains indirect holdings or has adopted a scheduled trading plan.

Source: original release